Cancers are not just a bunch of invasive and malignant cells, but also complex “organs” consisting of many other recruited cells.
The tumor microenvironment (TME) is constructed by the interaction between malignant cells and non-transformed cells. Our Next-IO™ programs focus on the targets in tumor microenvironment that are related to immune cells. Cells in TME contain T lymphocytes,
B lymphocytes, natural killer (NK) and natural killer T (NKT) cells, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), tumor-associated neutrophils (TANs), cancer-associated fibroblasts,
adipocytes, vascular endothelial cells, pericytes, and lymphatic endothelial cells, etc. There are a wide range of pre-clinical and clinical approaches targeting tumor microenvironment. It is believed that TME is important in designing
novel cancer therapies. Please visit some sample programs as follows to learn more.
Fig.1 The Projected Timeline of Next-IO™ Programs.
Creative Biolabs provided unparalleled support in developing Alzheimer’s disease therapeutics. Their Next-IO™ program not only offered technical expertise but also ensured comprehensive monitoring and swift project advancement, making them a trusted partner in our research.
—Emily C., Neuroscience Researcher
Creative Biolabs provided excellent support for our monoclonal antibody project under the Next-IO™ program. The detailed profiling of immune cells in the tumor microenvironment allowed us to develop more precise therapeutic approaches. Their professionalism and timely delivery exceeded our expectations.
—Emma W., Senior Scientist
Working with Creative Biolabs on COVID-19-related therapeutic antibodies was highly productive. Their advanced Next-IO™ platforms helped us isolate potent candidates efficiently. The team's deep knowledge of immuno-oncology and smooth collaboration enabled rapid project progression.
—James R., Biotechnology Director
Creative Biolabs provided unparalleled support in developing Alzheimer’s disease therapeutics. Their Next-IO™ program not only offered technical expertise but also ensured comprehensive monitoring and swift project advancement, making them a trusted partner in our research.
—Emily C., Neuroscience Researcher
Creative Biolabs provided excellent support for our monoclonal antibody project under the Next-IO™ program. The detailed profiling of immune cells in the tumor microenvironment allowed us to develop more precise therapeutic approaches. Their professionalism and timely delivery exceeded our expectations.
—Emma W., Senior Scientist